Spire I & II
This Study Evaluated The Pcsk9 Inhibitor, Bococizumab (PF04950615;RN316), Compared To Placebo, In Reducing The Occurrence Of Major Cardiovascular Events:
- Cardiovascular Death
- Myocardial Infarction
- Stroke
- Unstable Angina Requiring Urgent Revascularization
Study Metrics
Sites Initiated
16
Sites Randomized
15
Patients Screened
442
Patients Randomized
114